Last Update 21 Feb 26

Fair value Decreased 27%

HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset

Humana's analyst fair value estimate has been reset from about $199.74 to $146.00. This reflects a broad wave of lower price targets as analysts factor in updated EPS guidance, Medicare Advantage margin uncertainty, and recent model revisions after Q4 results and regulatory developments.

Analyst Commentary

Recent Street research around Humana has tilted cautious, with a cluster of lowered price targets and downgrades following Q4 results, updated guidance, and regulatory headlines. While there are differing views on long term opportunity in government managed care, the near term narrative in this research set is centered on execution risk in Medicare Advantage, earnings visibility, and the impact of rate and cost assumptions on valuation.

Several bearish analysts have reset their targets to account for Humana's EPS guidance, which was set at over US$9, and for what they view as a wide range of possible outcomes tied to Medicare Advantage membership, margins, and regulatory updates. Some reports also reflect model changes after the latest Q4 release, as well as responses to Medicare rate notices that these analysts describe as negative for managed care.

Bearish Takeaways

Bearish analysts cut price targets materially, including reductions from levels around US$285 to US$200 and from US$290 to US$206. They frame Humana as a story where valuation needs to reflect higher execution and earnings risk rather than prior growth assumptions.
Several firms downgraded the stock or moved to more neutral stances after Q4, citing uncertainty around Medicare Advantage margins, the underlying profitability of rapid membership growth, and the potential impact of Medicare rate notices that they describe as a significant negative for managed care.
Reports highlight that EPS guidance at over US$9 still depends heavily on margin improvement on retained Medicare Advantage members. Bearish analysts see this as leaving a wide band of possible earnings outcomes if medical cost trends or rate decisions do not align with company expectations.
Some commentary around federal healthcare policy and upcoming Medicare Advantage rate decisions points to an environment where bearish analysts see limited room for error. In their view, Humana's valuation is increasingly sensitive to small changes in cost trends, membership mix, and regulatory terms.

What's in the News

Humana provided earnings guidance for fiscal 2026, indicating GAAP EPS of at least US$8.89. This sets a reference point for how the company is framing its multi year earnings outlook.
The company launched Agent Assist with Google Cloud AI to support more than 20,000 member advocates who handle up to 80 million calls annually. The initiative aims to make member support more personalized and efficient through real time call summaries and proactive guidance.
Humana entered a partnership with Carda Health to expand access to at home cardiac and pulmonary rehabilitation for older adults, including clinically supervised exercise, nutrition and medication follow ups, and functional capacity assessments.
Humana partnered with Atlas Oncology Partners to offer a more coordinated cancer care model for eligible Medicare Advantage members in Tennessee and Mississippi, with embedded care teams, psychosocial support, urgent virtual care access, and integrated communication between clinicians.
Broader sector headlines include congressional scrutiny of ACA insurers and debates in Washington over extending Obamacare subsidies and healthcare proposals, with Humana frequently cited among the major public companies in focus. (Axios, Wall Street Journal, MS Now, Politico)

Valuation Changes

Fair Value: Reset from about $199.74 to $146.00, a reduction of roughly 27% in the analyst fair value estimate.
Discount Rate: Held essentially steady at about 6.98%, indicating no material change in the rate used to discount future cash flows.
Revenue Growth: Assumed long term revenue growth moved from about 7.05% to roughly 9.10%, an increase of a little over 2 percentage points.
Net Profit Margin: Long term net profit margin assumption shifted from about 1.79% to roughly 1.65%, a modest reduction in expected profitability on each $1 of revenue.
Future P/E: Future P/E multiple moved from about 10.49x to roughly 7.74x, indicating a lower valuation multiple applied to projected earnings.

2 views

Key Takeaways

Heavy reliance on Medicare Advantage exposes Humana to regulatory changes, political reform risks, and competitive pressures, threatening future earnings stability and growth.
Rising healthcare costs, increased utilization, and tech-driven competition could compress margins and undermine long-term profitability if operational efficiencies are not achieved.
Strong membership and segment growth, operational efficiencies, and cost management are driving stable revenue, expanding margins, and supporting long-term earnings stability.

Catalysts

About Humana

Provides medical and specialty insurance products in the United States.What are the underlying business or industry changes driving this perspective?

Mounting federal and state budget deficits are expected to drive regulatory change and potential cost-cutting in government-sponsored health programs, which could lead to compressed reimbursement rates and directly reduce Humana's revenue growth in Medicare Advantage over the coming years.
Escalating political momentum for large-scale healthcare reform, including the possibility of a shift towards a single-payer or Medicare for All model, poses a significant existential threat to Humana's business model and would sharply curtail its future earnings power if such reforms were enacted.
Humana's heavy reliance on the Medicare Advantage market, which produces more than eighty percent of the company's revenue, leaves it highly vulnerable to negative changes in government reimbursement policy or heightened competition, risking declining revenue stability and long-term earnings growth.
Persistent upward pressure on healthcare costs and rising utilization-particularly in high-cost categories like specialty pharmacy and oncology-threatens to outpace premium growth, which could drive sustained net margin compression if Humana is unable to sufficiently control operating expenses.
Accelerating entry of tech-enabled competitors and ongoing consolidation among healthcare providers are likely to erode Humana's competitive moat and bargaining power, resulting in rising costs and reduced operating leverage that would constrain both revenue growth and future profitability.

Humana Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Humana compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Humana's revenue will grow by 2.5% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from 1.4% today to 1.9% in 3 years time.
The bearish analysts expect earnings to reach $2.4 billion (and earnings per share of $20.03) by about July 2028, up from $1.7 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 13.5x on those 2028 earnings, down from 16.0x today. This future PE is lower than the current PE for the US Healthcare industry at 20.9x.
Analysts expect the number of shares outstanding to grow by 0.24% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.4%, as per the Simply Wall St company report.

Humana Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Robust population and membership growth in key segments, including Medicare Advantage, CenterWell primary care, Medicaid, and specialty pharmacy, provides a strong foundation for future revenue expansion and mitigates the risk of long-term decline in the company's top line.
Sustained operational progress and investments in clinical excellence, quality (Stars performance), and technology-driven efficiencies point to meaningful opportunities for improved net margins and earnings over time, as the company continues to unlock cost savings and margin expansion.
Durable performance and positive trends in value-based care and primary care businesses, including successful integration of new clinics and consistent cohort maturation, support the company's ability to achieve higher lifetime value per member and expand profitability.
Expansion and diversification in the Medicaid segment, evidenced by new state contract wins and increasing scale, provide stable, recurring revenue streams and offset potential downside in more volatile or one-time market exits, supporting the company's earnings stability.
Ongoing implementation of cost management strategies, including increased use of AI and advanced analytics, are leading to lower general and administrative costs and increasing operating leverage, which are likely to drive sustainable improvements in earnings and operating margins in the long run.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Humana is $224.0, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Humana's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $402.23, and the most bearish reporting a price target of just $224.0.
In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $129.7 billion, earnings will come to $2.4 billion, and it would be trading on a PE ratio of 13.5x, assuming you use a discount rate of 6.4%.
Given the current share price of $226.56, the bearish analyst price target of $224.0 is 1.1% lower. The relatively low difference between the current share price and the analyst bearish price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Humana?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Reforms And Rising Costs Will Erode Medicare Margins